STOCK TITAN
  1. Home
  2. Sec-filings
  3. TNGX
  4. [Form 4] Tango Therapeutics, Inc. Insider Trading Activity

Tango Therapeutics, Inc. (TNGX) president exercises options and sells shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tango Therapeutics, Inc. reported that Crystal Adam, President, R&D, exercised stock options to acquire 27,000 shares of common stock at $5.20 per share and, on the same date, sold 27,000 shares in two tranches of 5,267 and 21,733 shares at weighted average prices of $26.7895 and $27.3509 per share. These transactions were effected under a Rule 10b5-1 trading plan adopted on October 27, 2025, and following the option exercise she held 287,040 stock options to purchase common shares.

Positive

  • None.

Negative

  • None.
Insider Crystal Adam
Role President, R&D
Sold 27,000 shs ($736K)
Approx. gross sale proceeds $736K
Approx. exercise cost $140K
Approx. pre-tax spread $595K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F1, F4 27,000 $0.00 $0.00
Exercise Common Stock F1 27,000 $5.20 $140K
Sale Common Stock F1, F2 5,267 $26.7895 $141K
Sale Common Stock F1, F3 21,733 $27.3509 $594K
Holdings After Transaction: Stock Option (Right to Buy) — 287,040 shares (Direct); Common Stock — 115,743 shares (Direct)
Footnotes (4)
  1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
  2. F2. Represents the weighted average sales price per share. The shares sold at prices ranging from $26.17 to $27.16 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. F3. Represents the weighted average sales price per share. The shares sold at prices ranging from $27.17 to $27.78 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  4. F4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.
Options exercised 27,000 shares Stock options converted to common stock on August 3, 2026
Option exercise price $5.20 per share Exercise price for 27,000 stock options into common stock
Shares sold 27,000 shares Common shares sold in two tranches on August 3, 2026
Weighted average sale price (tranche 1) $26.7895 per share 5,267 shares sold; individual trades ranged from $26.17 to $27.16
Weighted average sale price (tranche 2) $27.3509 per share 21,733 shares sold; individual trades ranged from $27.17 to $27.78
Options held after transaction 287,040 options Stock options to purchase common shares following the reported exercise
Rule 10b5-1 trading plan financial
"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price per share financial
"Represents the weighted average sales price per share. The shares sold at prices ranging"
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vest and become exercisable financial
"This option shall vest and become exercisable over a four-year period"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What transactions did Tango Therapeutics (TNGX) executive Crystal Adam report?
Crystal Adam, President, R&D, exercised options to acquire 27,000 Tango Therapeutics common shares at $5.20 and sold 27,000 shares the same day at weighted average prices of $26.7895 and $27.3509 per share.

At what prices did Crystal Adam sell Tango Therapeutics (TNGX) shares?
She sold 5,267 shares at a weighted average of $26.7895 per share within a $26.17–$27.16 range, and 21,733 shares at a weighted average of $27.3509 per share within a $27.17–$27.78 range.

What options did Crystal Adam exercise in this Tango Therapeutics (TNGX) filing?
Adam exercised stock options to purchase 27,000 Tango Therapeutics common shares at an exercise price of $5.20 per share. These options are part of a grant that vests over four years with an initial 25% vesting on February 27, 2024.

How many Tango Therapeutics (TNGX) options does Crystal Adam hold after the transaction?
After exercising 27,000 options, Adam held 287,040 stock options to purchase Tango Therapeutics common shares, as reported in the filing for the derivative security following the August 3, 2026 transaction.

Were Crystal Adam’s Tango Therapeutics (TNGX) trades made under a Rule 10b5-1 plan?
Yes. The filing states these transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025, indicating they followed a pre-established trading schedule rather than discretionary timing.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Crystal Adam
(Last)(First)(Middle)
C/O TANGO THERAPEUTICS, INC.,
201 BROOKLINE AVE., SUITE 901
(Street)
BOSTON MASSACHUSETTS 02215
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President, R&D
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/03/2026M(1)27,000A$5.2142,743D
Common Stock08/03/2026S(1)5,267D$26.7895(2)137,476D
Common Stock08/03/2026S(1)21,733D$27.3509(3)115,743D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$5.208/03/2026M(1)27,000 (4)03/01/2033Common Stock27,000$0287,040D
Explanation of Responses:
1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.
2. Represents the weighted average sales price per share. The shares sold at prices ranging from $26.17 to $27.16 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
3. Represents the weighted average sales price per share. The shares sold at prices ranging from $27.17 to $27.78 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
4. This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.
/s/ Julie Fogarty, as attorney-in-fact08/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR